<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="118006">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01566773</url>
  </required_header>
  <id_info>
    <org_study_id>PT001003</org_study_id>
    <nct_id>NCT01566773</nct_id>
  </id_info>
  <brief_title>PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD</brief_title>
  <official_title>A Randomized, Double Blind (Test Products and Placebo), Chronic Dosing (14 Days), Four Period, Eight Treatment, Placebo-Controlled, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Six Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide, Open Label) as An Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to determine an optimal dose and dosing regimen of
      PT001 MDI for further evaluation in later stage studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess efficacy relative to placebo of GP MDI in
      subjects with moderate to severe chronic obstructive pulmonary disease (COPD) within the
      range of doses evaluated in this protocol. To this end, each dose of GP MDI will be compared
      to placebo with respect to the primary efficacy endpoint, FEV1 AUC0-12 relative to baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-12</measure>
    <time_frame>14 days</time_frame>
    <description>Forced expiratory volume in 1 second area under the curve (FEV1 AUC0-12) relative to baseline following chronic dosing (14 days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak change in FEV1</measure>
    <time_frame>Day 1</time_frame>
    <description>Highest value of FEV1 post dose on day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of action</measure>
    <time_frame>Day 1</time_frame>
    <description>Time to reach ≥10% improvement on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak change in Inspiratory Capacity (IC)</measure>
    <time_frame>Day 1</time_frame>
    <description>Peak change in Inspiratory Capacity (IC) mean of 1 and 2 hour post-dose assessments minus the baseline</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva® Handihaler® (Tiotropium Bromide)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001 MDI</intervention_name>
    <description>Administered as two puffs BID for 14 days</description>
    <arm_group_label>PT001 MDI (Dose 1)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 2)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 3)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 4)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 5)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide</intervention_name>
    <description>Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI</description>
    <arm_group_label>Spiriva® Handihaler® (Tiotropium Bromide)</arm_group_label>
    <other_name>Spiriva® Handihaler®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001 Placebo MDI</intervention_name>
    <arm_group_label>PT001 Placebo MDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of &lt; or = 0.70

          -  A measured post- bronchodilator FEV1 &gt; or = 750ml or 30% predicted and &lt; or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other inclusion/exclusion criteria as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 14, 2013</lastchanged_date>
  <firstreceived_date>March 27, 2012</firstreceived_date>
  <firstreceived_results_disposition_date>October 22, 2013</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
